Abstracts tagged "anti-CCP antibodies"

Abstract Number: 1483 • 2016 ACR/ARHP Annual Meeting
Elevated Anti-Cyclic Citrullinated Peptide Antibody Titer Is Associated with Increased Cardiovascular Risk
Sarah A. Fantus¹, Melissa R. Bussey², Rochella A. Ostrowski³, Andrew Heisler¹ and Kyle Carey⁴, ¹Internal Medicine, Loyola University Medical Center, Maywood, IL, ²Division of Allergy, Immunology, and Rheumatology, Loyola University Medical Center, Maywood, IL, ³Rheumatology, Loyola University Medical Center, Maywood, IL, ⁴Clinical Research Office, Loyola University Chicago, Maywood, IL
Background/Purpose: Rheumatoid arthritits (RA) patients have an increased risk of mortality from cardiovascular (CV) disease. Proposed adaptation of CV risk score models in RA patients…
Abstract Number: 1976 • 2016 ACR/ARHP Annual Meeting
Ultrasound Inflammation in Patients Presenting with Arthralgia Is Associated with Developing Arthritis
Myrthe van der Ven¹, Marjolein Van der Veer-Meerkerk¹, David F. Ten Cate², Nigara Rasappu³, Marc R. Kok⁴, Dora Csakvari⁵, Johanna M.W. Hazes², Andreas H. Gerards⁶ and Jolanda J. Luime³, ¹Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands, ²Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands, ³Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ⁴Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁵Rheumatology, Erasmus University Medical Centre, ROTTERDAM, Netherlands, ⁶Rheumatology, Vlietland Hospital, Schiedam, Netherlands
Background/Purpose: To further decrease the burden of RA we need to identify patients early, preferably in absence of clinical apparent synovitis. Recent studies in US…
Abstract Number: 2117 • 2016 ACR/ARHP Annual Meeting
B Cell Phenotype and in Vitro Function in Patients with Rheumatoid Arthritis Developing Low Serum Immunoglobulins after Multiple Cycles of Rituximab
Geraldine Cambridge¹, Rita A. Moura², Venkat Reddy³ and Maria J. Leandro¹, ¹Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ²Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Repeat treatment with rituximab (RTX) predisposes some patients with rheumatoid arthritis (RA) to develop low levels of serum immunoglobulins (Igs). Understanding B cell function…
Abstract Number: 2416 • 2016 ACR/ARHP Annual Meeting
Antibodies to Citrullinated Peptides in Patients with Juvenile Idiopathic Arthritis and Rheumatoid Arthritis: Shared Expression of the Inherently Autoreactive 9G4 Idiotype
Hannah Peckham¹, Lauren Bourke¹, Anna Radziszewska¹, Maria J. Leandro², Debajit Sen¹, Geraldine Cambridge² and Yiannis Ioannou¹, ¹Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Rheumatoid factor (RF) positive polyarticular JIA (RF+ve pJIA) frequently progresses into adulthood with a clinical phenotype that ressembles rheumatoid arthritis (RA). Antibodies to cyclic…
Abstract Number: 2608 • 2016 ACR/ARHP Annual Meeting
Anti-CCP Antibody Titers Decrease with Altered B-Cell Subpopulation in RA Patients Treated with Tocilizumab
Atsushi Noguchi^1,2, Shinsuke Yasuda¹, Ryo Hisada¹, Kazumasa Ohmura¹, Sanae Shimamura¹, Yuka Shimizu¹, Masaru Kato¹, Kenji Oku¹, Toshiyuki Bohgaki¹, Olga Amengual¹, Tetsuya Horita¹, Miho Suzuki³, Yoshihiro Matsumoto⁴ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Product research department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ⁴Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Consecutive RA patients who initiated treatment with TCZ between December 2013 and September 2015 were enrolled in our prospective study. All patients met 2010…
Abstract Number: 494 • 2016 ACR/ARHP Annual Meeting
Sensitivity and Specificity of 14-3-3η, Anti-CEP-1 and Anti-Sa Antibodies in a Cohort of Seronegative and Suspected Rheumatoid Arthritis (RA) Patients from a Community Rheumatology Practice
Dmitry Karayev¹, Guoqiu Shen¹, Yvonne Lam¹, Andrew Rimmer¹, Nayan Lal¹, Eugene Karayev¹, Kristine Azarraga¹, Ronald A. Blum¹, Allan L. Metzger¹, Robert I. Morris¹ and Arash A. Horizon², ¹Rheumatology Diagnostics Laboratory, Inc. (RDL), Los Angeles, CA, ²Center for Rheumatology Medical Group, Los Angeles, CA
Background/Purpose: RA is the most common autoimmune inflammatory joint disease, affecting up to 1% of the world population. Detection of antibodies, specifically against IgM rheumatoid…
Abstract Number: 3017 • 2016 ACR/ARHP Annual Meeting
Elevated Neutrophil Extracellular Trap Levels Correlate with Anti-CCP3-IgG and Anti-CCP3-IgA Levels in the Sputum of Individuals at-Risk for Future Rheumatoid Arthritis
M. Kristen Demoruelle¹, Monica Purmalek², Heather Rothfuss³, Michael Weisman⁴, Lindsay Kelmenson¹, Michael Mahler⁵, Jill M. Norris⁶, Brian Cherrington³, Mariana Kaplan², V. Michael Holers¹ and Kevin D. Deane¹, ¹Rheumatology Division, University of Colorado Denver, Aurora, CO, ²Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Zoology and Physiology, University of Wyoming, Laramie, WY, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Research and Development, Inova Diagnostics, San Diego, CA, ⁶Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: The initial site of anti-citrullinated protein antibody (ACPA) generation in RA has been proposed to be a mucosal site. We have previously demonstrated ACPA…
Abstract Number: 503 • 2016 ACR/ARHP Annual Meeting
Anti-CCP Titer and Prevalence Is Influenced By Age at Rheumatoid Arthritis Onset- Analysis Based on a Nationwide Database in Japan
Eri Kato¹, Tetsuji Sawada¹, Koichiro Tahara², Haeru Hayashi², Mayu Tago², Hiroaki Mori², Shigeru Yoshizawa³, Jinju Nishino⁴, Toshihiro Matsui⁵ and Shigeto Tohma⁶, ¹Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, ²Rheumatology, Tokyo Medical University, Tokyo, Japan, ³Department of Rheumatology, Fukuoka Hospital, National Hospital Organization, Fukuoka, Japan, ⁴Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, ⁵Lifetime Clinical Immunology, Tokyo Medical and Dental University, Tokyo, Japan, ⁶Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: Previous studies demonstrated the lower prevalence of anti-CCP antibody and rheumatoid factor (RF) in elderly-onset rheumatoid arthritis (EORA). However, anti-CCP antibody titer in EORA…
Abstract Number: 507 • 2016 ACR/ARHP Annual Meeting
Comparison of Body Mass Index, Anti-Citrullinated Peptides Antibodies Status and Periodontal Condition in First Degree Relatives Individuals to Rheumatoid Arthritis
Sonia Unriza-Puin¹, Wilson Bautista-Molano^2,3, Gloria Lafaurie⁴, Rafael R. Valle-Oñate⁵, Phillipe Chalem⁶, Lorena Chila³, Juan Manuel Bello⁷ and Consuelo Romero Sanchez^3,8, ¹Unit of Oral Basic Investigation, School of Dentistry, Universidad El Bosque, Bogota, Colombia, ²Rheumatology Department School of Medicine HMC / UMNG, Bogotá, Colombia, ³Unit of Oral Basic Investigation, School of Dentistry, Universidad El Bosque, Bogotá, Colombia, ⁴Unit of Oral Basic Investigation-UIBO, School of Dentistry, Universidad El Bosque, Bogotá, Colombia, ⁵Rheumatology, Rheumatology Department School of Medicine HMC / UMNG, Bogota, Colombia, ⁶Fundación Instituto de Reumatología Fernando Chalem, Bogotá, Colombia, ⁷Rheumatology Department School of Medicine HMC / UMNG, Bogota, Colombia, ⁸Rheumatology, School of Medicine HMC / UMNG, Bogota, Colombia
Background/Purpose: Association studies in rheumatoid arthritis (RA) have been focused in the pre-clinical phases of the disease in asymptomatic individuals with higher risk to develop…
Abstract Number: 509 • 2016 ACR/ARHP Annual Meeting
Association of Anti-Citrullinated Protein Antibody Positivity and Titer Levels to Low Hand BMD, and the Consequence of Low Hand BMD on DAS28 (CRP) Remission in Established RA: Findings from a US Observational Cohort
H Ahmad¹, E Alemao¹, Z Guo¹, M Frits², Michael Weinblatt² and N A Shadick², ¹Bristol-Myers Squibb, Princeton, NJ, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hand bone mineral density (BMD) loss is an independent predictor of radiographic joint progression,1 and a potential indicator of vertebral and non-vertebral fracture risk.2…
Abstract Number: 536 • 2016 ACR/ARHP Annual Meeting
Precision Medicine in Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis on the Diagnostic Accuracy of Anti-CCP Tests for the Diagnosis of Rheumatoid Arthritis
Gaia Gallo¹, Barbara Mascialino¹, Donna Fountain², Kevin Cadwell² and Sigrid Sjolander¹, ¹Immuno Diagnostics, Thermo Fisher Scientific, Uppsala, Sweden, Uppsala, Sweden, ²PHMR, Berkeley Works, Berkley Grove, London, London, United Kingdom
Background/Purpose: Biological markers are objective molecular indicators possessing diagnostic, prognostic and predictive utility. The detection of antibodies to cyclic citrullinated peptides (Anti-CCP) may occur long…
Abstract Number: 1599 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics of Interstitial Lung Disease (ILD) in Rheumatoid Arthritis (RA) Patients in High Resolutional CT (HRCT) and Titer of Anti Citrullinated Peptide Antibodies (anti-CCP2)
Masaomi Yamasaki, Rheumatology, Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan
Background/Purpose: To investigate clinical characteristics of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients. And to analyze whether high resolutional CT (HRCT) and anti…
Abstract Number: 1641 • 2015 ACR/ARHP Annual Meeting
B Cell Depletion with Rituximab in Patients with Rheumatoid Arthritis: Multiplex Bead Array Reveals Kinetics of IgG and IgA Autoantibodies to Citrullinated Antigens
Geraldine Cambridge¹, Lauren J. Lahey², Maria J. Leandro¹, William H. Robinson³ and Jeremy Sokolove⁴, ¹Rheumatology, University College London, London, United Kingdom, ²Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ³VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁴Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA
Background/Purpose: Seropositivity for rheumatoid factors and anti-citrullinated (Cit) protein antibodies (ACPA) are the strongest predictor for clinical response to rituximab (RTX) in rheumatoid arthritis (RA).…
Abstract Number: 1740 • 2015 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibodies and Inflammatory Bowel Disease
Jaita Mukherjee¹, Maria Mouyis¹, Kavina Shah¹, Mohammad Mahdi Saeidinejad¹, Ayesha Akbar² and Shahir Hamdulay¹, ¹Rheumatology, Northwick Park Hospital, Middlesex, United Kingdom, ²Gastroenterology, Northwick Park Hospital, Middlesex, United Kingdom
Background/Purpose: Enteropathic arthropathy refers to the pattern of inflammatory arthritis seen in association with gastrointestinal pathology. Arthritis in the presence of inflammatory bowel disease can…
Abstract Number: 104 • 2015 ACR/ARHP Annual Meeting
A Genome-Wide Association Study Identifies SLC8A3 As a Susceptibility Locus for ACPA-Positive Rheumatoid Arthritis
Antonio Julià¹, Isidoro González-Alvaro², Antonio Fernandez-Nebro³, Francisco Blanco⁴, Benjamin Fernandez Gutierrez⁵, Antonio Gonzalez⁶, Juan D. Cañete⁷, Joan Maymo⁸, Mercedes Alperi-López⁹, Alejandro Olivé¹⁰, Hector Corominas¹¹, Víctor Martínez Taboada¹², Alba Erra¹³, Simon Sanchez Fernandez¹⁴, Arnald Alonso¹, María López-Lasanta¹, Raül Tortosa¹, S. Louis Bridges Jr.¹⁵, Jesús Tornero¹⁶ and Sara Marsal¹⁷, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, ³Rheumatology, Hospital Universitario Carlos Haya, Malaga, Spain, ⁴Rheumatology Division, Fundación Profesor Novoa Santos, A Coruna, Spain, ⁵Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁶H. Clinico Universtiario de Santiago, Santiago de Compostela, Spain, ⁷Unitat d’Artritis, Servei de Reumatologia, Hospital Clínic de Barcelona and Institut d’Investigacions Biomèdiques August Pí i Sunyer, Barcelona, Spain, ⁸H del Mar, Barcelona, Spain, ⁹Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ¹⁰Hospital Germans Trias i Pujol, Badalona, Spain, ¹¹Servei de Reumatologia, Hospital Moises Broggi, Barcelona, Spain, ¹²Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ¹³CapiCAT group (Nailfold Capillaroscopy group from the Catalan Society for Rheumatology)., Catalonia, Spain, ¹⁴Rheumatology Department, Hospital General La Mancha Centro, Ciudad Real, Spain, ¹⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁶Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ¹⁷Rheumatology Research Unit, Vall d'Hebron Hospital, Barcelona, Spain
Background/Purpose: Rheumatoid Arthritis (RA) patients with serum anti-citrullinated peptide antibodies (ACPA) have a strong and specific genetic background. We performed a genome-wide association study (GWAS)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.